These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17868340)

  • 1. Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt pathway.
    Lane D; Cartier A; Rancourt C; Piché A
    Int J Gynecol Cancer; 2008; 18(4):670-6. PubMed ID: 17868340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
    Lane D; Robert V; Grondin R; Rancourt C; Piché A
    Int J Cancer; 2007 Sep; 121(6):1227-37. PubMed ID: 17534891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latent membrane protein 1 mediates the resistance of nasopharyngeal carcinoma cells to TRAIL-induced apoptosis by activation of the PI3K/Akt signaling pathway.
    Li SS; Yang S; Wang S; Yang XM; Tang QL; Wang SH
    Oncol Rep; 2011 Dec; 26(6):1573-9. PubMed ID: 21850380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation.
    Kang YC; Kim KM; Lee KS; Namkoong S; Lee SJ; Han JA; Jeoung D; Ha KS; Kwon YG; Kim YM
    Cell Death Differ; 2004 Dec; 11(12):1287-98. PubMed ID: 15297884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
    Kandasamy K; Srivastava RK
    Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
    Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically.
    Li SS; Tang QL; Wang SH; Chen YH; Liu JJ; Yang XM
    Tumori; 2011; 97(6):762-70. PubMed ID: 22322844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus.
    Tong Y; Zhu W; Huang X; You L; Han X; Yang C; Qian W
    Oncol Rep; 2014 Apr; 31(4):1581-8. PubMed ID: 24535016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
    Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
    Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells.
    Goncharenko-Khaider N; Lane D; Matte I; Rancourt C; Piché A
    Oncogene; 2010 Oct; 29(40):5523-36. PubMed ID: 20661217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
    Chen X; Thakkar H; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
    Oncogene; 2001 Sep; 20(42):6073-83. PubMed ID: 11593415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Chen KF; Yeh PY; Hsu C; Hsu CH; Lu YS; Hsieh HP; Chen PJ; Cheng AL
    J Biol Chem; 2009 Apr; 284(17):11121-33. PubMed ID: 19261616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
    Yang J; Li G; Zhang K
    Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways.
    Thanaketpaisarn O; Waiwut P; Sakurai H; Saiki I
    Int J Oncol; 2011 Jul; 39(1):279-85. PubMed ID: 21537836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential response of neuroblastoma cells to TRAIL is independent of PI3K/AKT.
    Efron PA; Chen MK; Iyengar M; Dai W; Nagaram A; Beierle EA
    J Pediatr Surg; 2006 Jun; 41(6):1072-80. PubMed ID: 16769337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of combining tumor necrosis factor related apoptosis-inducing ligand with PI3-K-Akt inhibition on nasopharyngeal carcinoma cell].
    Li SS; Tang QL; Wang SH; Chen YH; Liu JJ; Wang S; Yang XM
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Oct; 46(10):854-8. PubMed ID: 22321426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.